MedTrace Logo

Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects

NCT05088343 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2021-10-21

No results posted yet for this study

Summary

Effect of hetrombopag on the pharmacokinetics of rosuvastatin in healthy subjects.

Conditions

  • Healthy Subjects

Interventions

DRUG

Rosuvastatin

Single oral dose of rosuvastatin on Day 1 or co-administered with hetrombopag on Day 11.

DRUG

Hetrombopag

7.5 mg hetrombopag was administered on Day 6 to Day 11.

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Xueying Ding · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-07
Primary Completion
2021-01-16
Completion
2021-01-16

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05088343 on ClinicalTrials.gov